Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals, Inc. reports news on the commercialization of PALSONIFY and the development of therapies for endocrine diseases and endocrine-related tumors. The company’s lead product, PALSONIFY (paltusotine), is a once-daily oral treatment approved for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. Recurring updates include product revenue, commercial launch activity, regulatory approvals and submissions, and financial results.
Crinetics’ pipeline news also covers paltusotine in carcinoid syndrome associated with neuroendocrine tumors, atumelnant in congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682 for SST2-expressing neuroendocrine tumors and other solid tumors. The company also reports discovery work involving GPCR-targeted small molecules and other endocrine targets.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the early release of late-breaking abstracts for ENDO 2024, focusing on a Phase 2 study of atumelnant (CRN04894) for Congenital Adrenal Hyperplasia (CAH). Initial data from four subjects were submitted, with plans to present extended results from six subjects in cohort 1 and more in cohort 2 at ENDO 2024. Detailed findings will be shared on June 3, 2024, during the Late-Breaking Poster Presentation session.
Crinetics Pharmaceuticals announced on May 10, 2024, the granting of non-qualified stock options to fifteen new non-executive employees under the 2021 Employment Inducement Incentive Award Plan. The options have an exercise price of $48.00 per share and will vest over four years. This inducement is pursuant to Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals reported strong financial results for Q1 2024, highlighted by positive data from Phase 2 studies of Atumelnant (CRN04894) in congenital adrenal hyperplasia and ACTH-dependent Cushing’s Syndrome. The company is set to present late-breaking results at ENDO in June. Additionally, a Phase 3 study for paltusotine in carcinoid syndrome is expected to start by year-end. Crinetics also secured $350 million in financing to support commercial readiness and pipeline development, totaling $901.0 million in cash and equivalents as of March 31, 2024.
Crinetics Pharmaceuticals will present advancements from their Atumelnant (CRN04894) and Paltusotine development programs at ENDO 2024. Initial data from the Phase 2 trial of Atumelnant in Congenital Adrenal Hyperplasia and findings from the Phase 1b/2a ACTH-Dependent Cushing’s Syndrome trial will be showcased. Data from Phase 3 PATHFNDR 1 and 2 trials of Paltusotine in Acromegaly, along with new long-term safety and efficacy findings, will also be presented. Crinetics aims to build the premier endocrine-focused pharmaceutical company with these developments.
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) will report its first quarter 2024 financial results on May 9, 2024. The company will host a conference call to discuss financial results and provide a business update. Investors can participate via phone or webcast.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.